12488289

Source:http://linkedlifedata.com/resource/pubmed/id/12488289

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0030705, umls-concept:C0034656, umls-concept:C0210630, umls-concept:C0282461, umls-concept:C0332173, umls-concept:C1136535
pubmed:issue	1
pubmed:dateCreated	2002-12-18
pubmed:abstractText	We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with daily administration of filgrastim, in the provision of neutrophil support.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/12488289-12488286
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Filgrastim, http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating..., http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/docetaxel, http://linkedlifedata.com/resource/pubmed/chemical/pegfilgrastim
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	0923-7534
pubmed:author	pubmed-author:BaselgaJJ, pubmed-author:ClemensM RMR, pubmed-author:GalidAA, pubmed-author:GasconPP, pubmed-author:GreenM DMD, pubmed-author:GuillemVV, pubmed-author:International Pegfilgrastim 749 Study Group, pubmed-author:KoelblHH, pubmed-author:LalisangR IRI, pubmed-author:LiangB CBC, pubmed-author:PiccartM JMJ, pubmed-author:RenwickJJ, pubmed-author:SamoniggHH, pubmed-author:SienaSS, pubmed-author:ZaniVV
pubmed:issnType	Print
pubmed:volume	14
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	29-35
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:12488289-Adult, pubmed-meshheading:12488289-Aged, pubmed-meshheading:12488289-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12488289-Breast Neoplasms, pubmed-meshheading:12488289-Delayed-Action Preparations, pubmed-meshheading:12488289-Double-Blind Method, pubmed-meshheading:12488289-Doxorubicin, pubmed-meshheading:12488289-Drug Administration Schedule, pubmed-meshheading:12488289-Female, pubmed-meshheading:12488289-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:12488289-Humans, pubmed-meshheading:12488289-Middle Aged, pubmed-meshheading:12488289-Neoplasm Staging, pubmed-meshheading:12488289-Neutropenia, pubmed-meshheading:12488289-Neutrophils, pubmed-meshheading:12488289-Paclitaxel, pubmed-meshheading:12488289-Recombinant Proteins, pubmed-meshheading:12488289-Taxoids
pubmed:year	2003
pubmed:articleTitle	A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
pubmed:affiliation	Royal Melbourne Hospital, Melbourne, Australia. michael.green@mh.org.au
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Comment, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III